Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
European Journal of Endocrinology|September 3, 2013
Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-upG Ntali, A Asimakopoulou, T Siamatras, et al.
Pituitary|August 21, 2012
A consensus on the diagnosis and treatment of acromegaly complicationsS Melmed, F F Casanueva, A Klibanski, et al.
Clinical Endocrinology|April 6, 2005
Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-upN Karavitaki, C Brufani, J T Warner, et al.
Clinical Endocrinology|November 23, 2007
Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotideN Karavitaki, H E Turner, C B T Adams, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 9, 2011
Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persistsL A Bradbury, S Barlow, F Geoghegan, et al.
Clinical Endocrinology|September 26, 2007
Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effectiveJ S Bevan, J Newell-Price, J A H Wass, et al.
Diabetologia|September 7, 2007
Disparate genetic influences on polycystic ovary syndrome (PCOS) and type 2 diabetes revealed by a lack of association between common variants within the TCF7L2 gene and PCOST M Barber, A J Bennett, C J Groves, et al.
The Journal of Clinical Endocrinology and Metabolism|November 10, 2005
A genome-wide screen in 1119 relative pairs with autoimmune thyroid diseaseJ C Taylor, S C Gough, P J Hunt, et al.
European Journal of Endocrinology|December 3, 2005
Consensus statement: medical management of acromegalyS Melmed, F Casanueva, F Cavagnini, et al.
The Journal of Clinical Endocrinology and Metabolism|October 5, 2002
Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor sizeJ S Bevan, S L Atkin, A B Atkinson, et al.
Pageof 5